Low-priced drugs headache for drug makers

Low-priced or exit-prevention medicines should be excluded from the current small drug package system, according to pharmaceutical sources.

These drugs are big headaches for pharmaceutical manufacturers as many firms have found it difficult to deal with ever-increasing stocks of these drugs in small bundles, said an official from a pharmaceutical firm.

Under the current regulation, drug m...